Combined neutral endopeptidase inhibitors

Expert Opinion on Investigational Drugs

Volumn 20, Issue 4, 2011, Pages 457-463

  Cuculi, Florim ^a   Erne, Paul ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

ACE inhibitors; angioedema; heart failure; hypertension; neuroendopeptidase inhibitors; omapatrilat

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENKEPHALINASE INHIBITOR; LISINOPRIL; OMAPATRILAT; PLACEBO; SAMPATRILAT; SINORPHAN; UNCLASSIFIED DRUG; VASOPEPTIDASE INHIBITOR;

ANGINA PECTORIS; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; APLASTIC ANEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PATHOPHYSIOLOGY; PULSE PRESSURE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT DURATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; HYPERTENSION; MODELS, BIOLOGICAL; NEPRILYSIN; PROTEASE INHIBITORS; PYRIDINES; RENIN-ANGIOTENSIN SYSTEM; THIAZEPINES;

EID: 79952675090     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.556617     Document Type: Review

References (48)

1. Lawes CM, Vander Hoorn S, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371(9623):1513-18
2. Meyer K, Simmet A, Arnold M, et al. Stroke events, and case fatalities in Switzerland based on hospital statistics and cause of death statistics. Swiss Med Wkly 2009;139(5-6):65-9
3. Conen D, Chae CU, Guralnik JM, Glynn RJ. Influence of blood pressure and blood pressure change on the risk of congestive heart failure in the elderly. Swiss Med Wkly 2010;140(13-14):202-8
4. Mancia G, De Backer G, Dominiczak A, et al. The task force for the management of arterial hypertension of the European Society of H, The task force for the management of arterial hypertension of the European Society of C. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28(12):1462-536
5. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362(9395):1527-35 (Pubitemid 37410190)
6. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;(1):CD002003
7. Saini-Chohan HK, Hatch GM. Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure. Curr Drug Metab 2009;10(3):206-19
8. Werner C, Poss J, Bohm M. Optimal antagonism of the Renin-Angiotensin- aldosterone system: do we need dual or triple therapy? Drugs 2010;70(10):1215-30
9. Krum H, Maggioni A. Renin inhibitors in chronic heart failure: the Aliskiren observation of heart failure treatment study in context. Clin Cardiol 2010;33(9):536-41
10. Corti R, Burnett JC Jr, Rouleau JL, et al. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation 2001;104(15):1856-62
11. Margulies KB, Barclay PL, Burnett JC Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995;91(7):2036-42
12. Graf K, Koehne P, Grafe M, et al. Regulation and differential expression of neutral endopeptidase 24.11 in human endothelial cells. Hypertension 1995;26(2):230-5
13. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989;3(2):145-51
14. Dussaule JC, Stefanski A, Bea ML, et al. Characterization of neutral endopeptidase in vascular smooth muscle cells of rabbit renal cortex. Am J Physiol 1993;264(1 Pt 2):F45-52
15. Stephenson SL, Kenny AJ. The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J 1987;243(1):183-7 (Pubitemid 17048899)
16. Lang CC, Motwani JG, Coutie WJ, Struthers AD. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clin Sci (Lond) 1992;82(6):619-23
17. Murphy LJ, Corder R, Mallet AI, Turner AJ. Generation by the phosphoramidon-sensitive peptidases, endopeptidase-24.11 and thermolysin, of endothelin-1 and c-terminal fragment from big endothelin-1. Br J Pharmacol 1994;113(1):137-42 (Pubitemid 24271729)
18. Ando S, Rahman MA, Butler GC, et al. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26(6 Pt 2):1160-6
19. Rouleau JL, Pfeffer MA, Stewart DJ, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356(9230):615-20 (Pubitemid 30627587)
20. Wallis EJ, Ramsay LE, Hettiarachchi J. Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther 1998;64(4):439-49 (Pubitemid 28473770)
21. Norton GR, Woodiwiss AJ, Hartford C, et al. Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects. Am J Hypertens 1999;12(6):563-71 (Pubitemid 29268387)
22. Allikmets K. Sampatrilat shire. Curr Opin Investig Drugs 2002;3(4):578-81
23. Dussaule JC, Grange JD, Wolf JP, et al. Effect of sinorphan, an enkephalinase inhibitor, on plasma atrial natriuretic factor and sodium urinary excretion in cirrhotic patients with ascites. J Clin Endocrinol Metab 1991;72(3):653-9
24. Varin J, Duboc D, Weber S, et al. Effect of sinorphan, an endopeptidase inhibitor on severe congestive cardiac insufficiency. Arch Mal Coeur Vaiss 1991;84(10):1465-71
25. Kahn JC, Patey M, Dubois-Rande JL, et al. Effect of sinorphan on plasma atrial natriuretic factor in congestive heart failure. Lancet 1990;335(8681):118-19 (Pubitemid 20018754)
26. Cleland JG, Swedberg K. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators. Lancet 1998;351(9116):1657-8 (Pubitemid 28252192)
27. Maertins T, von Keutz E, Goetze L. Acute, subchronic, and chronic toxicity of ecadotril in dogs. Am J Vet Res 2000;61(4):425-9 (Pubitemid 30174323)
28. O'Connor CM, Gattis WA, Gheorghiade M, et al. A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J 1999;138(6 Pt 1):1140-8
29. Neal B, MacMahon S, Ohkubo T, et al. Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. J Renin Angiotensin Aldosterone Syst 2002;3(4):270-6 (Pubitemid 36181997)
30. Regamey F, Maillard M, Nussberger J, et al. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men. Hypertension 2002;40(3):266-72 (Pubitemid 35006709)
31. Mitchell GF, Izzo JL Jr, Lacourciere Y, et al. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002;105(25):2955-61 (Pubitemid 34693826)
32. Palmieri V, Devereux RB, Hollywood J, et al. Association of pulse pressure with cardiovascular outcome is independent of left ventricular hypertrophy and systolic dysfunction: the Strong Heart Study. Am J Hypertens 2006;19(6):601-7 (Pubitemid 43775863)
33. Raitakari OT, Juonala M, Taittonen L, et al. Pulse pressure in youth and carotid intima-media thickness in adulthood: the cardiovascular risk in young Finns study. Stroke 2009;40(4):1519-21
34. Bangalore S, Messerli FH, Franklin SS, et al. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. Eur Heart J 2009;30(11):1395-401
35. Kostis JB, Packer M, Black HR, et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004;17(2):103-11 (Pubitemid 38125125)
36. Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation 2002;106(8):920-6 (Pubitemid 34925324)
37. Piedimonte G, Nadel JA, Long CS, Hoffman JI. Neutral endopeptidase in the heart. Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation. Circ Res 1994;75(4):770-9
38. Schriefer JA, Broudy EP, Hassen AH. Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion. J Pharmacol Exp Ther 2001;298(3):970-5 (Pubitemid 32761911)
39. Chaitman BR, Ivleva AY, Ujda M, et al. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. Am J Cardiol 2005;95(11):1283-9 (Pubitemid 40719857)
40. Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy 2010;40(1):50-61
41. Cuculi F, Suter Y, Erne P. Angioedema of the tongue. CMAJ 2008;178(9):1136 (Pubitemid 351580072)
42. Howes LG, Tran D. Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema? Drug Saf 2002;25(2):73-6
43. Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am 2006;26(4):725-37 (Pubitemid 44679724)
44. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332(7551):1177-81
45. Rubinstein I, Muns G, Zucker IH. Plasma exudation in conscious dogs with experimental heart failure. Basic Res Cardiol 1994;89(5):487-98
46. Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375(9722):1255-66
47. Klapholz M, Thomas I, Eng C, et al. Effects of omapatrilat on hemodynamics and safety in patients with heart failure. Am J Cardiol 2001;88(6):657-61 (Pubitemid 32831099)
48. McClean DR, Ikram H, Mehta S, et al. Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. J Am Coll Cardiol 2002;39(12):2034-41 (Pubitemid 34628287)